Cigna Group (NYSE:CI) Given Outperform Rating at Royal Bank Of Canada

Cigna Group (NYSE:CI)‘s stock had its “outperform” rating reaffirmed by equities research analysts at Royal Bank Of Canada in a research note issued on Thursday, Benzinga reports. They presently have a $337.00 target price on the health services provider’s stock. Royal Bank Of Canada’s price objective would indicate a potential upside of 25.84% from the stock’s previous close.

A number of other research firms have also recently issued reports on CI. Wells Fargo & Company upped their price target on shares of Cigna Group from $305.00 to $307.00 and gave the company an “equal weight” rating in a report on Friday, July 31st. Guggenheim increased their price target on shares of Cigna Group from $338.00 to $361.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Evercore started coverage on shares of Cigna Group in a research note on Wednesday, September 9th. They set an “in-line” rating and a $290.00 target price for the company. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Cigna Group in a research report on Thursday, August 27th. Finally, Wolfe Research restated an “outperform” rating and set a $315.00 price objective on shares of Cigna Group in a research report on Tuesday, June 16th. Fifteen research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $337.10.

Cigna Group Trading Down 1.5%

Cigna Group stock traded down $4.02 during midday trading on Thursday, reaching $267.81. The stock had a trading volume of 803,678 shares, compared to its average volume of 1,678,191. The stock’s 50-day simple moving average is $279.53 and its 200 day simple moving average is $280.55. The company has a debt-to-equity ratio of 0.68, a quick ratio of 0.76 and a current ratio of 0.76. Cigna Group has a twelve month low of $239.51 and a twelve month high of $315.47. The stock has a market capitalization of $70.77 billion, a PE ratio of 11.09, a price-to-earnings-growth ratio of 0.93 and a beta of 0.31.

Cigna Group (NYSE:CI) last released its quarterly earnings data on Thursday, July 30th. The health services provider reported $7.78 EPS for the quarter, beating the consensus estimate of $7.60 by $0.18. The company had revenue of $71.56 billion for the quarter, compared to analyst estimates of $70.14 billion. Cigna Group had a return on equity of 19.75% and a net margin of 2.27%.The firm’s revenue was up 6.7% compared to the same quarter last year. During the same period last year, the company posted $7.20 earnings per share. Cigna Group has set its FY 2026 guidance at 30.450- EPS. Analysts expect that Cigna Group will post 30.51 EPS for the current year.

Insider Activity at Cigna Group

In other Cigna Group news, insider Everett Neville sold 617 shares of Cigna Group stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $284.05, for a total transaction of $175,258.85. Following the completion of the sale, the insider directly owned 5,053 shares in the company, valued at approximately $1,435,304.65. The trade was a 10.88% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Nicole Jones sold 2,677 shares of Cigna Group stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $279.61, for a total transaction of $748,515.97. Following the sale, the insider owned 25,880 shares of the company’s stock, valued at approximately $7,236,306.80. The trade was a 9.37% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 22,730 shares of company stock worth $6,293,359. 0.60% of the stock is owned by insiders.

Institutional Trading of Cigna Group

Several hedge funds have recently added to or reduced their stakes in the company. GQG Partners LLC purchased a new stake in shares of Cigna Group during the 2nd quarter worth $1,628,918,000. Bank of America Corp DE purchased a new position in shares of Cigna Group during the 2nd quarter worth about $827,692,000. Legal & General Group Plc purchased a new stake in shares of Cigna Group during the 2nd quarter valued at $542,779,000. Boston Partners increased its position in Cigna Group by 314.6% during the 4th quarter. Boston Partners now owns 1,638,191 shares of the health services provider’s stock worth $450,856,000 after purchasing an additional 1,243,056 shares in the last quarter. Finally, The Manufacturers Life Insurance Company acquired a new stake in Cigna Group during the 2nd quarter worth approximately $241,312,000. Institutional investors and hedge funds own 86.99% of the company’s stock.

Cigna Group News Roundup

Here are the key news stories impacting Cigna Group this week:

• Positive Sentiment: Cigna introduced its “Lead to One” strategy, focusing on complex care, specialty pharmacy, affordability, personalization, data, technology and artificial intelligence. Management targets 10%–14% adjusted EPS compound annual growth through 2030, offering a potentially significant long-term earnings-growth catalyst. Cigna Investor Day announcement
• Positive Sentiment: The company plans to invest $3 billion in a multiyear modernization and productivity initiative. Although costly initially, Cigna expects the program to improve workflow, performance and operating efficiency. Increased investment in specialty pharmacy and complex care could also strengthen Evernorth’s competitive position. Cigna specialty pharmacy investment article
• Positive Sentiment: Royal Bank of Canada reaffirmed an “outperform” rating and set a $337 price target, implying roughly 26% upside from the cited share price. A separate Seeking Alpha analysis characterized CI as undervalued and forecast double-digit EPS growth. Cigna valuation analysis
• Neutral Sentiment: Cigna reaffirmed its 2026 EPS guidance of approximately $30.45 and revenue guidance of $280 billion. The company also announced an exclusive agreement involving Cigna’s international health benefits business and UnitedHealthcare Global, potentially supporting its international platform, although the financial impact was not specified. Cigna international agreement
• Negative Sentiment: The 2026 revenue outlook of $280 billion is below the roughly $287.2 billion analyst consensus, while EPS guidance of $30.45 is slightly below the $30.51 consensus estimate. The $3 billion investment program may also create near-term expense and execution concerns, helping explain why the stock has decreased despite the favorable long-term targets. Cigna financial targets

Cigna Group Company Profile

The Cigna Group (NYSE: CI) is a global health company that provides health care and related services to individuals, employers, government organizations and health plans. Its operations are primarily organized through Cigna Healthcare and Evernorth Health Services, which together address health coverage, pharmacy services, care delivery and benefit management.

Cigna Healthcare offers medical, dental, behavioral health, disability and other benefits, with a focus on employer-sponsored and individual health plans in the United States as well as international health services.